FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Roberto Padrini

Research Profile

Concepts & Ideas

Chemicals & Drugs

Living Beings

Guinea Pigs

Disorders

Procedures

Anatomy

Hearts

Physiology

Genotype

Co-author Network

Publications

TOP 3
Alessandra Nisi; Marco Panfili; Giovanni Boffa; Giovanni De Rosa; Francesca Groppa; Milena Gusella; Roberto Padrini
Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation.
Marco Panfili; Silvia Secco; Giovanni De Rosa; Francesca Groppa; Massimo Iafrate; Filippo Marzot; Roberto Padrini
Ranolazine-induced severe bladder hypotonia.
Milena Gusella; Laura Bertolaso; Caterina Bolzonella; Felice Pasini; Roberto Padrini
Frequency of uridine monophosphate synthase Gly(213)Ala polymorphism in Caucasian gastrointestinal cancer patients and healthy subjects, investigated by means of new, rapid genotyping assays.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Roberto Padrini (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alessandra Nisi; Marco Panfili; Giovanni Boffa; Giovanni De Rosa; Francesca Groppa; Milena Gusella; Roberto Padrini
Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation.
Journal of clinical pharmacology 2013;53(1):51-7.
2012: Marco Panfili; Silvia Secco; Giovanni De Rosa; Francesca Groppa; Massimo Iafrate; Filippo Marzot; Roberto Padrini
Ranolazine-induced severe bladder hypotonia.
The Annals of pharmacotherapy 2012;46(9):e24.
2011: Milena Gusella; Laura Bertolaso; Caterina Bolzonella; Felice Pasini; Roberto Padrini
Frequency of uridine monophosphate synthase Gly(213)Ala polymorphism in Caucasian gastrointestinal cancer patients and healthy subjects, investigated by means of new, rapid genotyping assays.
Genetic testing and molecular biomarkers 2011;15(10):691-5.
2011: Shoaib Afzal; Jon Trærup Andersen; Carmen Barile; Laura Bertolaso; Kasper Brødbæk; Barna Budai; Milena Gusella; Erika Hitre; Søren Astrup Jensen; Espen Jimenez-Solem; Judit Kralovánszky; István Láng; Eniko Orosz; Roberto Padrini; Felice Pasini; Morten Petersen; Ben Vainer; Ulla Vogel; Vilmos Adleff; Henrik Enghusen Poulsen
The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
Pharmacogenomics 2011;12(9):1257-67.
2011: Alessandra Casonato; Viviana Daidone; Roberto Padrini
Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease.
Seminars in thrombosis and hemostasis 2011;37(5):456-63.
2011: Shoaib Afzal; Jon T Andersen; Carmen Barile; Laura Bertolaso; Kasper Broedbaek; Milena Gusella; Søren Astrup Jensen; Espen Jimenez-Solem; Roberto Padrini; Felice Pasini; Morten Petersen; Ben Vainer; Ulla B Vogel; Henrik E Poulsen
Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(11):3822-9.
2011: Milena Gusella; Felice Pasini; Caterina Bolzonella; Silvia Meneghetti; Carmen Barile; Antonio Bononi; Silvia Toso; Daniela Menon; Giorgio Crepaldi; Yasmina Modena; Laura Stievano; Roberto Padrini
Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
British journal of clinical pharmacology 2011;71(3):437-44.
2011: Carlo-Federico Zambon; Vittorio Pengo; Roberto Padrini; Daniela Basso; Stefania Schiavon; Paola Fogar; Alessandra Nisi; Anna Chiara Frigo; Stefania Moz; Michela Pelloso; Mario Plebani
VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study.
Pharmacogenomics 2011;12(1):15-25.
2010: Roberto Padrini; Vittorio Pengo
Dosing of clopidogrel and aspirin in acute coronary syndromes.
The New England journal of medicine 2010;363(25):2465-6; author reply 2467-8.
2010: Alessandra Casonato; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Roberto Padrini; Antonella Bertomoro; Viviana Daidone; Antonio Pagnan
Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.
Haematologica 2010;95(8):1366-72.
2010: A-K Hamberg; Mia Wadelius; Jonatan D Lindh; Marja-Liisa Dahl; Roberto Padrini; Panos Deloukas; Anders Rane; E Niclas Jonsson
A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age.
Clinical pharmacology and therapeutics 2010;87(6):727-34.
2010: Alessandra Casonato; Lisa Gallinaro; Maria Grazia Cattini; Francesca Sartorello; Elena Pontara; Roberto Padrini; Antonella Bertomoro; Viviana Daidone; Antonio Pagnan
Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series.
Translational research : the journal of laboratory and clinical medicine 2010;155(4):200-8.
2008: Maryta Sztukowska; Lisa Gallinaro; Maria Grazia Cattini; Elena Pontara; Francesca Sartorello; V Daidone; Roberto Padrini; Antonio Pagnan; Alessandra Casonato
Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease.
British journal of haematology 2008;143(1):107-14.
2008: Lisa Gallinaro; Maria Grazia Cattini; Maryta Sztukowska; Roberto Padrini; Francesca Sartorello; Elena Pontara; Antonella Bertomoro; Viviana Daidone; Antonio Pagnan; Alessandra Casonato
A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor.
Blood 2008;111(7):3540-5.
2007: Milena Gusella; Eros Ferrazzi; Roberto Padrini
Classification of thymidylate synthase gene enhancer region polymorphisms.
International journal of cancer. Journal international du cancer 2007;121(11):2580; author reply 2580.
2007: Milena Gusella; Roberto Padrini
G>C SNP of thymidylate synthase with respect to colorectal cancer.
Pharmacogenomics 2007;8(8):985-96.
2007: A-K Hamberg; Marja-Liisa Dahl; M Barban; Maria Gabriella Scordo; Mia Wadelius; Vittorio Pengo; Roberto Padrini; E Niclas Jonsson
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.
Clinical pharmacology and therapeutics 2007;81(4):529-38.
2006: Milena Gusella; Giorgio Crepaldi; C Barile; Antonio Bononi; Daniela Menon; Sivia Toso; D Scapoli; L Stievano; Eros Ferrazzi; F Grigoletto; M Ferrari; Roberto Padrini
Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(11):1656-60.
2006: Milena Gusella; C Bolzonella; Giorgio Crepaldi; Eros Ferrazzi; Roberto Padrini
A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele.
The pharmacogenomics journal 2006;6(6):421-4.
2006: Rocco Orlando; Roberto Padrini; Mauro Perazzi; Sara De Martin; Pierpaolo Piccoli; Pietro Palatini
Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
Clinical pharmacology and therapeutics 2006;79(5):489-99.
2006: Marianna Fantin; Luigi Quintieri; Erzsébet Kúsz; Emese Kis; Hristos Glavinas; Maura Floreani; Roberto Padrini; Erno Duda; Csaba Vizler
Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties.
European journal of pharmacology 2006;535(1-3):301-9.
2006: Alessandra Casonato; Elena Pontara; Francesca Sartorello; Maria Grazia Cattini; Lisa Gallinaro; Antonella Bertomoro; Antonio Rosato; Roberto Padrini; Antonio Pagnan
Identifying type Vicenza von Willebrand disease.
The Journal of laboratory and clinical medicine 2006;147(2):96-102.
2006: Harumi Takahashi; Grant R Wilkinson; Edith A Nutescu; Takashi Morita; Marylyn Ritchie; Maria Gabriella Scordo; Vittorio Pengo; Martina Barban; Roberto Padrini; Ichiro Ieiri; Kenji Otsubo; Toshitaka Kashima; Sosuke Kimura; Shinichi Kijima; Hirotoshi Echizen
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.
Pharmacogenetics and genomics 2006;16(2):101-10.
2005: Milena Gusella; Mirca Rebeschini; Giuseppe Cartei; Eros Ferrazzi; Mariano Ferrari; Roberto Padrini
Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure.
Therapeutic drug monitoring 2005;27(6):816-8.
2005: Roberto Padrini; Cristina Canova; Piero Conz; Elena Mancini; Emanuela Rizzioli; Antonio Santoro
Convective and adsorptive removal of beta2-microglobulin during predilutional and postdilutional hemofiltration.
Kidney international 2005;68(5):2331-7.
2005: Hugo Kohnke; Maria Gabriella Scordo; Vittorio Pengo; Roberto Padrini; Mia Wadelius
Apolipoprotein E (APOE) and warfarin dosing in an Italian population.
European journal of clinical pharmacology 2005;61(10):781-3.
2004: Harumi Takahashi; Grant R Wilkinson; Roberto Padrini; Hirotoshi Echizen
CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.
Clinical pharmacology and therapeutics 2004;75(5):376-80.
2004: Rocco Orlando; Pierpaolo Piccoli; Sara De Martin; Roberto Padrini; Maura Floreani; Pietro Palatini
Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function.
Clinical pharmacology and therapeutics 2004;75(1):80-8.
2003: Roberto Padrini; Mariano Ferrari
Pharmacogenetics.
The New England journal of medicine 2003;348(20):2041-3; author reply 2041-3.
2003: Rocco Orlando; Pierpaolo Piccoli; Sara De Martin; Roberto Padrini; Pietro Palatini
Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
British journal of clinical pharmacology 2003;55(1):86-93.
2002: Maria Gabriella Scordo; Vittorio Pengo; Edoardo Spina; Marja-Liisa Dahl; Milena Gusella; Roberto Padrini
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.
Clinical pharmacology and therapeutics 2002;72(6):702-10.
2002: Maria Ornella Nicoletto; Roberto Padrini; Manlio Palumbo; Azzam Ziade; Roberto S Ragazzi; Graziella Pratesi; Grazia Artioli; Michelandrea De Cesare; Franco Zunino
Intralesional topotecan in advanced ovarian cancer: a clinical report, based on a preclinical study.
Oncology reports 2002;9(6):1351-4.
2002: Milena Gusella; Sivia Toso; Eros Ferrazzi; Mariano Ferrari; Roberto Padrini
Relationships between body composition parameters and fluorouracil pharmacokinetics.
British journal of clinical pharmacology 2002;54(2):131-9.
2002: Rocco Orlando; Michele Mussap; Mario Plebani; Pierpaolo Piccoli; Sara De Martin; Maura Floreani; Roberto Padrini; Pietro Palatini
Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis.
Clinical chemistry 2002;48(6 Pt 1):850-8.
2002: Milena Gusella; Eros Ferrazzi; Mariano Ferrari; Roberto Padrini
New limited sampling strategy for determining 5-fluorouracil area under the concentration-time curve after rapid intravenous bolus.
Therapeutic drug monitoring 2002;24(3):425-31.
2002: Alessandra Casonato; Elena Pontara; Francesca Sartorello; Maria Grazia Cattini; Maria Teresa Sartori; Roberto Padrini; Antonio Girolami
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.
Blood 2002;99(1):180-4.
2001: R Brandolese; Maria Gabriella Scordo; Edoardo Spina; Milena Gusella; Roberto Padrini
Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.
Clinical pharmacology and therapeutics 2001;70(4):391-4.
2000: Pietro Palatini; Maura Floreani; Roberto Padrini; Pierpaolo Piccoli; M Bertoli; L Calò; Rocco Orlando
Effects of chronic renal failure and hemodialysis on the monoethylglycinexylidide liver function test.
Clinical chemistry 2000;46(9):1406-8.
2000: Maria Ornella Nicoletto; Roberto Padrini; F Galeotti; Eros Ferrazzi; Giuseppe Cartei; F Riddi; Manlio Palumbo; Massimo De Paoli; A Corsini
Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer.
Cancer chemotherapy and pharmacology 2000;45(6):457-62.
2000: Rocco Orlando; Maura Floreani; Eleonora Napoli; Roberto Padrini; Pietro Palatini
Renal clearance of N(1)-methylnicotinamide: a sensitive marker of the severity of liver dysfunction in cirrhosis.
Nephron 2000;84(1):32-9.
1999: Roberto Padrini; Marco Panfili; G Magnolfi; D Piovan; Dino Casarotto; Mariano Ferrari
Myocardial region (right or left ventricle) and aetiology of heart failure can influence the inotropic effect of ouabain in failing human myocardium.
British journal of clinical pharmacology 1999;48(5):743-9.
1999: Rocco Orlando; Maura Floreani; Roberto Padrini; Pietro Palatini
Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis.
Clinical nephrology 1999;51(6):341-7.
1998: Rocco Orlando; Maura Floreani; Roberto Padrini; Pietro Palatini
Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: equivalence of systemic and renal clearances as glomerular filtration markers.
British journal of clinical pharmacology 1998;46(6):605-9.
1998: D Piovan; G Magnolfi; M Ferrari; Roberto Padrini
Neurohumoral effects of digitalis.
American heart journal 1998;136(5):928-30.
1998: PA Miglioli; F Merlo; E Grabocka; Roberto Padrini
Effects of cardio-pulmonary bypass on vancomycin plasma concentration decay.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;38(4):275-8.
1997: Roberto Padrini; Milena Gusella; M Al Bunni; D Piovan; R Zordan; G Magnolfi; P Maiolino; Mariano Ferrari
Tolerance to the repolarization effects of rac-sotalol during long-term treatment.
British journal of clinical pharmacology 1997;44(5):463-70.
1997: Q Yang; Roberto Padrini; D Piovan; Mariano Ferrari
Cardiac effects of quinidine on guinea-pig isolated perfused hearts after in vivo quinidine pretreatment.
British journal of pharmacology 1997;122(1):7-12.
1997: Roberto Padrini; G Speranza; Giandomenico Nollo; Sergio Bova; D Piovan; Renzo Antolini; Mariano Ferrari
Adaptation of the QT interval to heart rate changes in isolated perfused guinea pig heart: influence of amiodarone and D-sotalol.
Pharmacological research : the official journal of the Italian Pharmacological Society 1997;35(5):409-16.
1997: PA Miglioli; F Merlo; A Fabbri; Roberto Padrini
Teicoplanin concentrations in serum, pericardium, pericardial fluid and thoracic wall fat in patients undergoing cardio-pulmonary bypass surgery.
The Journal of antimicrobial chemotherapy 1997;39(2):229-33.
1997: Sergio Bova; Gabriella Cargnelli; E D'Amato; S Forti; Q Yang; Lucia Trevisi; Patrizia Debetto; Lorenzo Cima; sisto luciani; Roberto Padrini
Calcium-antagonist effects of norbormide on isolated perfused heart and cardiac myocytes of guinea-pig: a comparison with verapamil.
British journal of pharmacology 1997;120(1):19-24.
1996: Roberto Padrini; M Panfili; Luca Testolin; F Pesarin; D Piovan; G Magnolfi; Ugolino Livi; Dino Casarotto; Sergio Dalla Volta
Evaluation of the regional responsivity to ryanodine of human myocardium from patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathies.
Basic research in cardiology 1996;91(5):361-6.
1996: Sergio Bova; L Trevisi; Patrizia Debetto; Lorenzo Cima; M Furnari; sisto luciani; Roberto Padrini; Gabriella Cargnelli
Vasorelaxant properties of norbormide, a selective vasoconstrictor agent for the rat microvasculature.
British journal of pharmacology 1996;117(6):1041-6.
1996: Santo Davide Ferrara; Luciano Tedeschi; Giampietro Frison; Rocco Orlando; M Mazzo; R Zordan; Roberto Padrini; P Palatini
Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
European journal of clinical pharmacology 1996;50(4):305-10.
1995: Q Yang; Roberto Padrini; Sergio Bova; D Piovan; G Magnolfi
Electrocardiographic interactions between pinacidil, a potassium channel opener and class I antiarrhythmic agents in guinea-pig isolated perfused heart.
British journal of pharmacology 1995;114(8):1745-9.
1995: D Piovan; Roberto Padrini; G Svalato Moreolo; G Magnolfi; Ornella Milanesi; R Zordan; P A Pellegrino; Mariano Ferrari
Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment.
Therapeutic drug monitoring 1995;17(1):60-7.
1995: PA Miglioli; F Merlo; F Campanile; Roberto Padrini
Effects of cardiopulmonary bypass on teicoplanin serum disposition.
International journal of clinical pharmacology research 1995;15(1):23-5.
1993: Roberto Padrini; D Piovan; A Javarnaro; Francesco Cucchini; Mariano Ferrari
Pharmacokinetics and electrophysiological effects of intravenous ajmaline.
Clinical pharmacokinetics 1993;25(5):408-14.
1993: R Zordan; Roberto Padrini; V Bernini; D Piovan; Mariano Ferrari
Influence of age and gender on the in vitro serum protein binding of flecainide.
Pharmacological research : the official journal of the Italian Pharmacological Society 1993;28(3):259-64.
1993: Roberto Padrini; D Piovan; M Busa; M al-Bunni; P Maiolino; Mariano Ferrari
Pharmacodynamic variability of flecainide assessed by QRS changes.
Clinical pharmacology and therapeutics 1993;53(1):59-64.
1993: P Palatini; Luciano Tedeschi; Giampietro Frison; Roberto Padrini; R Zordan; Rocco Orlando; L Gallimberti; Gian Luigi Gessa; Santo Davide Ferrara
Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers.
European journal of clinical pharmacology 1993;45(4):353-6.
1992: Roberto Padrini; D Piovan; E Gaglione; R Zordan; Mariano Ferrari
Determination of lorajmine and its metabolite ajmaline in plasma and urine by a new high-performance liquid chromatographic method.
Therapeutic drug monitoring 1992;14(5):391-6.
1992: Sergio Bova; Roberto Padrini; W F Goldman; Dora Berman-Weinberg; Gabriella Cargnelli
On the mechanism of vasodilating action of berberine: possible role of inositol lipid signaling system.
The Journal of pharmacology and experimental therapeutics 1992;261(1):318-23.
1992: Roberto Padrini; Sergio Bova; Gabriella Cargnelli; D Piovan; M Ferrari
Effects of pinacidil on guinea-pig isolated perfused heart with particular reference to the proarrhythmic effect.
British journal of pharmacology 1992;105(3):715-9.
1992: D Piovan; Roberto Padrini; G Svaluto Moreolo; P A Pellegrino; Mariano Ferrari
Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment.
Pharmacological research : the official journal of the Italian Pharmacological Society 1992;25 Suppl 1():81-2.
1991: Roberto Padrini; L Compostella; D Piovan; A Javarnaro; Francesco Cucchini; Mariano Ferrari
Ajmaline test in a patient with chronic renal failure. A pharmacokinetic and pharmacodynamic study.
Clinical pharmacokinetics 1991;21(2):150-4.
1989: Roberto Padrini; G Speranza; Giandomenico Nollo; Sergio Bova; D Piovan; Renzo Antolini
Dynamic adaptation of QT interval to heart rate changes: influence of amiodarone and D-sotalol.
Pharmacological research : the official journal of the Italian Pharmacological Society 1989;21 Suppl 1():143-4.
1989: Sergio Bova; Roberto Padrini; Gabriella Cargnelli; D Piovan; M Ferrari
The influence of acidosis on the myocardial uptake and electrocardiographic effects of disopyramide.
European journal of pharmacology 1989;168(2):179-85.
1989: Luisa Zanolla; Paolo Marino; Giorgio Golia; Maria Antonia Prioli; Roberto Padrini; Piero Zardini
[Variations in left ventricular function during chronic therapy with verapamil in angina patients. Influence of the plasma concentration of the drug. Quantitative M-mode echocardiographic analysis].
Giornale italiano di cardiologia 1989;19(7):591-7.
1989: Gabriella Cargnelli; D Piovan; Sergio Bova; Roberto Padrini; M Ferrari
Present and future trends in research and clinical applications of inodilators.
Journal of cardiovascular pharmacology 1989;14 Suppl 8():S124-32.
1988: Carlo Merkel; Angelo Gatta; Massimo Bolognesi; Roberto Padrini; G F Finucci; Paolo Angeli; A Ruol
The calcium-channel blocker, verapamil, does not improve portal pressure in patients with alcoholic cirrhosis.
British journal of clinical pharmacology 1988;26(3):273-7.
1988: M Ferrari; D Piovan; Roberto Padrini; Sergio Bova; R Moretto; Gabriella Cargnelli
[Anti-arrhythmia drugs of the '80s: something new with respect for the old].
Cardiologia (Rome, Italy) 1988;33(4):343-6.
1988: G F Finucci; Roberto Padrini; D Piovan; E Melica; Carlo Merkel; Angelo Gatta; R Zuin
Verapamil pharmacokinetics and liver function in patients with cirrhosis.
International journal of clinical pharmacology research 1988;8(2):123-6.
1987: Franco Rengo; M Ferrari; Nicola Ferrara; N Guerra; R Moretto; L Odierna; Roberto Padrini
[Correlation between the clinical efficacy and pharmacokinetic profile of gallopamil].
Cardiologia (Rome, Italy) 1987;32(11):1243-8.
1987: Roberto Padrini; D Piovan; Sergio Bova; R Moretto; Gabriella Cargnelli; M Ferrari
Physiological, pharmacological and pathological factors affecting the pharmacokinetics of calcium entry blockers.
Giornale italiano di cardiologia 1987;17(9):786-90.
1987: Gabriella Cargnelli; Roberto Padrini; D Piovan; R Moretto; Sergio Bova
Effects of SAS 1310, a new calcium antagonist, on isolated myocardial and smooth muscle preparations.
European journal of pharmacology 1987;136(2):163-70.
1987: Roberto Padrini; D Piovan; R Moretto
Column liquid chromatographic determination of prajmalium in plasma and urine by direct sample injection.
Journal of chromatography 1987;415(1):183-7.
1986: M Ferrari; Roberto Padrini; D Piovan; Sergio Bova; R Moretto; Gabriella Cargnelli
The myocardial levels of the antiarrhythmic drugs: clinical relevance.
Giornale italiano di cardiologia 1986;16(8):660-2.
1986: D Piovan; Roberto Padrini; M Furlanut; R Moretto; M Ferrari
Plasma and tissue levels of flecainide in rats.
Pharmacological research communications 1986;18(8):739-45.
1985: Luisa Zanolla; Roberto Padrini; D Piovan; D Olivieri; P Zardini
Plasma levels of verapamil and its major metabolites during long-term oral treatment, in chronic stable angina. Correlation with the clinical effects of the drug.
Cardiologia (Rome, Italy) 1985;30(5):369-73.
1985: M Ferrari; Roberto Padrini; D Piovan; Sergio Bova; Gabriella Cargnelli
[Pharmacology of calcium antagonists].
Cardiologia (Rome, Italy) 1985;30 Suppl 2():7-14.
1985: Roberto Padrini; E Barbieri; D Piovan; M Toffoli; A Motta; Gian Paolo Trevi; M Ferrari
Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man.
European journal of clinical pharmacology 1985;28(6):653-7.
1985: E Barbieri; Roberto Padrini; D Piovan; M Toffoli; Gabriella Cargnelli; Gian Paolo Trevi; M Ferrari
Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
International journal of clinical pharmacology research 1985;5(2):99-107.
1984: Luisa Zanolla; Gian Paolo Trevi; A Rizzo; Roberto Padrini; D Piovan; D Olivieri; P Zardini
Long-term persistence of antianginal effect of oral verapamil in chronic stable angina.
Journal of cardiovascular pharmacology 1984;6(3):423-8.
1983: F Furlanello; G Inama; P Dal Forno; Roberto Padrini; D Piovan; A C Pessina
Amiodarone in the antiarrhythmic therapy.
Pharmacological research communications 1983;15(10):881-900.
1983: F Furlanello; Marcello Disertori; G Vergara; M Guarnerio; P Dal Forno; Roberto Padrini; S Gobbato; M Ferrari
Clinical evaluation of new antiarrhythmic agents: experiences with propafenone.
International journal of clinical pharmacology research 1983;3(2):101-5.
1982: F Furlanello; G Inama; M Ferrari; Roberto Padrini; D Piovan; M Guarnerio; G Vergara; A Del Favero; P Dal Forno; Marcello Disertori
Amiodarone and amiodarone plus digitalis in the treatment of paroxismal supraventricular reciprocating tachyarrhythmias.
Pharmacological research communications 1982;14(8):731-7.
1982: Gabriella Cargnelli; Roberto Padrini; D Piovan; G Piacenza; M Ferrari; V Gallucci
A report on the positive inotropic action of amrinone.
Bollettino della Società italiana di biologia sperimentale 1982;58(13):793-9.
1982: Roberto Padrini; PA Miglioli; E Casiglia; D Piovan; M Ferrari
[Experimental and clinical pharmacokinetics of amrinone].
Cardiologia (Rome, Italy) 1982;27(1):103-6.
1982: M Ferrari; Gabriella Cargnelli; D Piovan; Sergio Bova; Roberto Padrini
[New inotropic drugs].
Giornale italiano di cardiologia 1982;12(2):139-46.
1981: F Furlanello; G Inama; M Ferrari; Roberto Padrini; M Guarnerio; G Vergara; P Dal Forno; R Bettini; Marcello Disertori
[Another type of interaction between blood levels of digitalis and anti-arrhythmic drugs: digoxin and amiodarone. Experience with long-term therapy].
Giornale italiano di cardiologia 1981;11(11):1725-8.
1981: M Ferrari; Gabriella Cargnelli; B Dona; Paola Dorigo; S Gobbato; Francesco Maddalena; I Maragno; Roberto Padrini; R Russo; L Schivazappa; A C Pessina
[Cardiovascular pharmacology in the 1970's].
Giornale italiano di cardiologia 1981;11 Suppl 1():355-86.
1980: Gabriella Cargnelli; P Finotti; S Gobbato; Roberto Padrini
[Effects of aprindine on the electromechanical coupling of the myocardium and smooth muscle].
Bollettino della Società italiana di biologia sperimentale 1980;56(5):474-80.